THE SQL Server Blog Spot on the Web

Welcome to SQLblog.com - The SQL Server blog spot on the web Sign in | |
in Search

Adam Machanic

Adam Machanic, Boston-based SQL Server developer, shares his experiences with programming, monitoring, and performance tuning SQL Server. And the occasional battle with the query optimizer.

SQL Saturday Chicago...and the Gentle Art of Planscaping!

Three weeks from now I'll be visiting Chicago to participate in SQL Saturday. I'll offer two different learning opportunities:

On Friday, April 25, you can join me for a full day seminar on parallelism and performance in SQL Server. This class covers in-depth background on the hows and whys behind SQL Server's parallel processing, followed by an investigation of advanced techniques that you can use to improve performance of some queries by an order of magnitude or more. The class is filling up, so make sure to register soon!

On Saturday, April 26, I'll deliver my newest talk, "Clash of the Row Goals." I unveiled it the first time this past weekend at SQL Saturday Boston, and Joe Chang happened to blog about it a few hours ago. In this talk you'll learn how to shape and modify query plans by leveraging an understanding of query optimizer internals -- without using query hints. I've decided to call this technique planscaping. The idea is to create beautiful query plans that perform well and don't break at unexpected times. That's a good thing, right?

Hope to see you in Chicago!


Published Wednesday, April 02, 2014 6:31 PM by Adam Machanic

Comment Notification

If you would like to receive an email when updates are made to this post, please register here

Subscribe to this post's comments using RSS

Comments

 

medchemexpress said:

Phase III clinical study of complicated intra-abdominal infections within AstraZeneca's new antibiotic drugs CAZ-AVI treatment was a complete success

August 21, 2014 News - Phase III clinical study AstraZeneca recently announced the development of new antibiotics CAZ-AVI (ceftazidime-avibactam) treatment of complicated intra-abdominal infections (cIAI) achieved satisfactory results.<a href="http://www.medchemexpress.com/Caspofungin-Acetate.html">Caspofungin Acetate</a>, The results showed that CAZ-AVI in the treatment of cIAI patients (including cephalosporins by anti-bacteria cIAI statin-induced) when equally effective with meropenem.

The phase III clinical study using the RECLAIM-1 and RECLAIM-2 experimental design. Active ingredients CAZ-AVI is constituted by the treatment of serious bacterial infections cephalosporin statins and β-lactamase inhibitor new avibactam. CAZ-AVI in <a href="http://www.medchemexpress.com/Avibactam.html">avibactam</a> statins can protect cephalosporins are not decomposed by the resistant bacteria secreted β-lactamase, thereby maintaining bacterial toxicity. The antibiotic used to treat a range of drug-resistant Gram-negative bacteria. The clinical study also evaluated different doses of CAZ-AVI in clinical efficacy and safety. The results showed that the clinical efficacy of meropenem CAZ-AVI, the patients were randomly assigned basically administered 28-35 days in recovery.<a href="http://www.medchemexpress.com/Micafungin-sodium.html">Micafungin sodium</a> , While its side effects are not higher than that of meropenem, clinical CAZ-AVI showing the main side effects were diarrhea, vomiting, nausea and fever.

AstraZeneca said researchers excited about the results, but also revealed that currently CAZ-AVI research hospital for urinary tract infections and pneumonia also is well underway.

Ten years ago, due to lower profits and diverse variety of antibiotics, including many pharmaceutical giant AstraZeneca all have to exit the antibiotics market.<a href="http://www.medchemexpress.com/Febuxostat.html">Febuxostat</a>, However, in recent years, drug-resistant bacteria in the global blowout situation, so that these pharmaceutical giants and national medical management department aware of a serious crisis and opportunity, many pharmaceutical manufacturers have re-return to the market, devote their energies to the development of new antibiotics.

October 22, 2014 4:19 AM

Leave a Comment

(required) 
(required) 
Submit

About Adam Machanic

Adam Machanic is a Boston-based SQL Server developer, writer, and speaker. He focuses on large-scale data warehouse performance and development, and is author of the award-winning SQL Server monitoring stored procedure, sp_WhoIsActive. Adam has written for numerous web sites and magazines, including SQLblog, Simple Talk, Search SQL Server, SQL Server Professional, CoDe, and VSJ. He has also contributed to several books on SQL Server, including "SQL Server 2008 Internals" (Microsoft Press, 2009) and "Expert SQL Server 2005 Development" (Apress, 2007). Adam regularly speaks at conferences and training events on a variety of SQL Server topics. He is a Microsoft Most Valuable Professional (MVP) for SQL Server, a Microsoft Certified IT Professional (MCITP), and an alumnus of the INETA North American Speakers Bureau.

This Blog

Syndication

Powered by Community Server (Commercial Edition), by Telligent Systems
  Privacy Statement